V-Bio Ventures
V-Bio Ventures is a Belgian life science venture capital fund manager founded in 2015 that manages €186M across two funds, investing in early- to mid-stage therapeutics companies across Europe with a preferred relationship with VIB.
- Company typePrivate
- Founded2015
- HeadquartersGent, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What V-Bio Ventures does
V-Bio Ventures is an independent Belgian life science venture capital fund manager founded in 2015 and headquartered in Ghent, Belgium. The firm manages €186 million across two funds (Fund I at €76M final close in December 2016 and Fund II at €110M final close in March 2022) and invests in approximately 30 early- to mid-stage private companies focused on therapeutics — drug discovery and drug development — with a geographic remit spanning Europe and selective opportunities beyond. V-Bio sources deals primarily through a preferred, co-founder-level relationship with VIB (the Flanders Institute for Biotechnology) and additionally from European research institutes, academic spin-outs, entrepreneurial initiatives, and corporate spin-outs; the firm also co-creates startups from academic IP and takes board seats in portfolio companies.
The firm does not develop proprietary technology. Its "product" is capital plus hands-on company-building services: financing for clinical development and commercialization, strategic guidance, board participation, network access, and syndication with co-investors. Portfolio companies span modalities including GPCR antibody therapeutics (Confo), Treg cell therapies (Dualyx), molecular glues (Orionis), antibody-drug conjugates (ATB Therapeutics, Avidicure), fibrosis (Agomab), radiopharmaceuticals (Precirix), cardiovascular (Corteria), neuromuscular disease (Augustine), obesity (Tanai), vaccines (AstriVax), and agricultural biologicals (Protealis, RootWave, Aphea.Bio). The team comprises three Managing Partners (Christina Takke, Willem Broekaert, Shelley Margetson), two Partners (Ward Capoen, Katja Rosenkranz), one Venture Partner (Mathias Falcenberg, joined February 2025), a Finance Manager (Martin Solleveld), and an Advisor (Tom Schwarz), supported by institutional LP capital from EIF, InnovFin/EFSI/EU, Korys, ARKimedes, KU Leuven, UGent, Gimv, BNP Paribas Fortis Private Equity, and FPIM/SFPI.
Revenue mechanics follow the standard VC model: recurring management fees on committed capital (~1.5–2.5% of AUM annually) plus lumpy carried interest on successful exits. Notable realized liquidity events include the Syndesi Therapeutics acquisition by AbbVie (March 2022) and the Confo Therapeutics worldwide licensing agreement with Lilly for CFTX-1554 ($40M upfront, up to $590M in milestones, March 2023). The Orionis–Genentech collaborations ($105M upfront in the second deal, May 2025) and Augustine Therapeutics' oversubscribed €78M Series A (March 2025) further validate portfolio momentum.
V-Bio Ventures firmographics
Firmographics- Name
- V-Bio Ventures
- Legal name
- V-Bio Ventures
- Website
- http://v-bio.ventures
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- V-Bio Ventures is a Belgian life science venture capital fund manager founded in 2015 that manages €186M across two funds, investing in early- to mid-stage therapeutics companies across Europe with a preferred relationship with VIB.
- Ownership category
- akta.pro rank
V-Bio Ventures industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment Management
- NAICS
- Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where V-Bio Ventures is headquartered
LocationHeadquarters
- HQ city
- Gent
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
V-Bio Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Management Fees and Carried Interest: V-Bio generates revenue through management fees on funds under management and carried interest (performance fees) from successful portfolio company exits. As a VC fund, they co-create and invest in early-stage life science companies with the expectation of returns through M&A, licensing deals, or IPOs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
V-Bio Ventures product offering
Product offeringCore offering
V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. The firm manages €186 million across two funds focused on therapeutics (drug discovery and drug development), targeting private companies with differentiated technology addressing unmet needs. V-Bio contributes more than capital by providing strategic guidance, mentorship, network access, and active board participation to portfolio companies.
Product overview
V-Bio Ventures operates as a dual-fund life science venture capital platform managing €186 million across two funds (Fund I at €76M and Fund II at €110M). The firm offers three integrated offerings: its core investment funds targeting early/mid-stage therapeutics companies, startup co-creation services that leverage the VIB partnership to build companies from scientific discoveries, and access to a curated portfolio of approximately 15 portfolio companies. The fund focuses primarily on European biotech with a preferred relationship with Belgium-based VIB research institute, while also sourcing deals from other top research organizations throughout Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- V-Bio Ventures Fund I V-Bio Ventures' first venture capital fund focused on early-stage life science investments, which achieved final closing at over €76 million. The fund targeted private companies with differentiated technology addressing unmet needs in therapeutics and adjacent life science sectors.
- V-Bio Ventures Fund II V-Bio Ventures' second venture capital fund, raised to €110 million, continuing the firm's early/mid-stage life science investment strategy across Europe with a thematic focus on therapeutics.
- Startup Co-Creation Services
Quantifiable outcome
- Successful exits including Syndesi Therapeutics acquired by AbbVie
- +1 more outcomes
Companies that use V-Bio Ventures
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
V-Bio Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
V-Bio Ventures partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VIB (Flanders Institute for Biotechnology)coreV-Bio Ventures has a preferred, co-founder relationship with VIB, one of the world's premier life science research institutes. Part of companies V-Bio co-creates are built on VIB-derived innovations. VIB is a co-founder and minor investor in V-Bio. The fund provides early access to VIB's pipeline of innovations and works closely with VIB's Technology Transfer Office.
Scale indicators3 records
Recent moves9 records
Expansion highlights5 records
V-Bio Ventures competitors and assessment
Company assessmentDirect peers
- Forbion: Forbion is a leading European life sciences VC firm headquartered in the Netherlands, actively investing in early to late-stage biotech and therapeutic companies. Two V-Bio Managing Partners previously worked at Forbion (Christina Takke as Partner; Mathias Falcenberg as investment professional), and Forbion is a direct comparable in stage, sector focus, and European biotech deal sourcing.
- LSP (Life Sciences Partners): LSP is a Netherlands-based European life sciences and healthcare VC firm investing across early and growth stages in therapeutics, medical devices, and digital health. V-Bio advisor Tom Schwarz co-founded LSP, making it a direct comparable in pan-European life sciences VC.
- BioGeneration Ventures (BGV): BGV is a Netherlands-based early-stage life sciences VC firm focused on European biotech startups, often co-investing with V-Bio (e.g., Tanai Therapeutics with Novo Nordisk). Highly comparable in stage, sector focus, and European biotech thesis.
- Thuja Capital Healthcare Fund: Thuja Capital is a Dutch early-stage life sciences and healthcare VC fund investing in therapeutics and medtech. V-Bio's Finance Manager Martin Solleveld has prior Thuja Capital experience; comparable stage and European life sciences focus.
- Gilde Healthcare: Gilde Healthcare is a Netherlands-based specialized healthcare investor covering therapeutics, medical devices, and healthcare services across Europe. Direct comparable in European early-stage healthcare VC, often co-investing in similar rounds.
- Kurma Partners: Kurma Partners is a France-based early-stage healthcare VC firm investing in therapeutics and digital health. Direct comparable in European life sciences VC stage, sector, and deal syndication.
Broad incumbents
- EQT Life Sciences (formerly LSP Investments): EQT Life Sciences is a large-scale, multi-stage life sciences investor operating venture and growth funds across Europe and the US with €2bn+ AUM. Functions as a broad incumbent comparable in sector and stage, though at much larger scale than V-Bio.
- HealthCap: HealthCap is a Nordic/European venture and growth investor focused on life sciences with over €1bn raised across funds. A comparable European specialist, though typically investing at larger check sizes than V-Bio.
- Andera Partners (Life Sciences): Andera Partners operates a dedicated life sciences practice within a broader European private equity platform, investing in therapeutics and medtech from early to growth stages. Comparable as a European life sciences investor.
- Sofinnova Partners: Sofinnova Partners is a leading European life sciences VC firm with multi-fund platforms spanning biotech, medtech, and industrial bio. Comparable in European biotech VC focus though at significantly larger AUM scale than V-Bio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
V-Bio Ventures social profiles
Digital presenceV-Bio Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
V-Bio Ventures leadership team
Management profileNumber of profiles
Profiles9 records
V-Bio Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
V-Bio Ventures M&A and investment
M&A and investmentM&A
Investments43 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about V-Bio Ventures
What does V-Bio Ventures do?
V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential. The firm manages €186 million across two funds focused on therapeutics (drug discovery and drug development), targeting private companies with differentiated technology addressing unmet needs. V-Bio contributes more than capital by providing strategic guidance, mentorship, network access, and active board participation to portfolio companies.
Is V-Bio Ventures a public or private company?
V-Bio Ventures is a private company. It is classified as management employee owned and is currently operating.
When was V-Bio Ventures founded?
V-Bio Ventures was founded in 2015. It employs 1 to 10 people.
Where is V-Bio Ventures based?
V-Bio Ventures is headquartered in Gent, Belgium, in the Europe region.
How does V-Bio Ventures make money?
One revenue line is on record: management Fees and Carried Interest.
Who are V-Bio Ventures's main competitors?
Direct peers on record are Forbion, LSP (Life Sciences Partners), BioGeneration Ventures (BGV), Thuja Capital Healthcare Fund, Gilde Healthcare and Kurma Partners. Broad incumbents are EQT Life Sciences (formerly LSP Investments), HealthCap, Andera Partners (Life Sciences) and Sofinnova Partners.
Does V-Bio Ventures have an API?
No public API is recorded for V-Bio Ventures.
What industry is V-Bio Ventures in?
V-Bio Ventures's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 5259 and its SIC code is 6282.